In Chinese breast cancer population (n = 772), no statistical significance was observed in pCR rate between mTNBC HER-2 low and HER-2 zero groups; however, in non-pCR groups, prognosis was significantly improved in HER-2 low, other than Her-2 zero group, consistent with our data (n = 50) [28]. This evidence concerns the gene ERBB2 and breast carcinoma.